Selected article for: "activity inhibit and lung inflammation"
Author: Iwabuchi, Keisuke; Yoshie, Koichiro; Kurakami, Yuichi; Takahashi, Kota; Kato, Yoshio; Morishima, Tsuneo
Title: Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases
  • Cord-id: uuor5hck
  • Document date: 2020_4_16
    • ID: uuor5hck
    Snippet: Abstract No specific and effective anti-viral treatment has been approved for COVID-19 so far. Systemic corticosteroid has been sometimes administered to severe infectious diseases combined with the specific treatment. However, as lack of the specific anti-SARS-CoV-2 drug, systemic steroid treatment has not been recommended for COVID-19. We report here three cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local infla
    Document: Abstract No specific and effective anti-viral treatment has been approved for COVID-19 so far. Systemic corticosteroid has been sometimes administered to severe infectious diseases combined with the specific treatment. However, as lack of the specific anti-SARS-CoV-2 drug, systemic steroid treatment has not been recommended for COVID-19. We report here three cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local inflammation with inhaled steroid that stays in the lung and to inhibit proliferation of the virus by antiviral activity. Larger and further studies are warranted to confirm the result of these cases.

    Search related documents:
    Co phrase search for related documents
    • abnormal pulmonary and acute phase: 1, 2, 3, 4
    • abnormal pulmonary and admission time: 1
    • abnormal pulmonary and liver damage: 1
    • acute exacerbation and admission time: 1, 2, 3
    • acute exacerbation and liver damage: 1
    • acute exacerbation and local inflammation: 1
    • acute phase and administration start: 1
    • acute phase and admission time: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and liver damage: 1, 2, 3, 4, 5, 6
    • acute phase and liver enzyme: 1, 2
    • acute phase and local inflammation: 1, 2
    • admission body temperature and liver enzyme: 1
    • admission time and liver damage: 1, 2, 3, 4, 5, 6
    • admission time and liver enzyme: 1, 2, 3
    • admission time and liver enzyme elevation diarrhea: 1